David Ma Schladt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
David Ma Schladt has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Ajay K. Israni
University of Texas Medical Branch, Galveston, Texas
6 shared publications - Arthur J. Matas
Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, USA
4 shared publications - Warren T. McKinney
Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA
4 shared publications - Casey R. Dorr
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, USA
3 shared publications - Pamala A. Jacobson
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, USA
3 shared publications - Roslyn Bernstein Mannon
University of Nebraska Medical Center, Omaha, USA
3 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by S. Karger AG in Organ Donation and Transplantation
- p. 1-18
Association of Willingness to Accept a Hepatitis C Status Donor Kidney on Access to Transplant
Introduction: The development of curative therapy for Hepatitis C (HCV) created the ability to safely utilize kidneys recovered from donors testing positive for HCV. We evaluate the association of kidney transplant candidates’ willingness to accept a HCV-positive donor kidney on access to deceased donor kidney transplant (DDKT), and the utilization of such donors kidneys more broadly. Methods: This study used data from the Scientific Registry of Transplant Recipients and included all candidates for DDKT on the waiting list between January 1, 2015, and March 12, 2020 (n = 233,033). Cox models with time to transplant were constructed to evaluate the association of willingness to accept a kidney from a HCV-positive donor with kidney transplant rate. Results: Willingness to accept a HCV-positive donor was associated with increased access to transplant for all waitlisted patients. Transplant rates for candidates willing to accept a HCV-positive donor were 0.296 transplants per person-years waiting compared to 0.132 transplants per person-years waiting for candidates who were never willing to accept such donors. In total, 8.3% of all waitlisted patients indicated willingness at listing while an additional 9.7% of the remaining waitlisted patients indicated willingness at later date with median time to willingness being 55 days (IQR: 0–719 days) after listing. Among waitlisted patients who were ever willing to accept a HCV-positive donor, 62.9% were male, 55.5% were White, and 51.4% attained a high school degree or higher. The numbers of DDKT using kidneys from HCV + donors increased during the study period; however, the nonuse of such kidneys has increased. Conclusion: Interventions targeting willingness to accept a HCV-positive donor may simultaneously increase access to transplant and support policies to reduce organ nonuse.
- 17 March 2026
- Published by S. Karger AG in Organ Donation and Transplantation
- p. 1-18
Open AccessAssociation of Willingness to Accept a Hepatitis C Status Donor Kidney on Access to Transplant
Introduction: The development of curative therapy for Hepatitis C (HCV) created the ability to safely utilize kidneys recovered from donors testing positive for HCV. We evaluate the association of kidney transplant candidates’ willingness to accept a HCV-positive donor kidney on access to deceased donor kidney transplant (DDKT), and the utilization of such donors kidneys more broadly. Methods: This study used data from the Scientific Registry of Transplant Recipients and included all candidates for DDKT on the waiting list between January 1, 2015, and March 12, 2020 (n = 233,033). Cox models with time to transplant were constructed to evaluate the association of willingness to accept a kidney from a HCV-positive donor with kidney transplant rate. Results: Willingness to accept a HCV-positive donor was associated with increased access to transplant for all waitlisted patients. Transplant rates for candidates willing to accept a HCV-positive donor were 0.296 transplants per person-years waiting compared to 0.132 transplants per person-years waiting for candidates who were never willing to accept such donors. In total, 8.3% of all waitlisted patients indicated willingness at listing while an additional 9.7% of the remaining waitlisted patients indicated willingness at later date with median time to willingness being 55 days (IQR: 0–719 days) after listing. Among waitlisted patients who were ever willing to accept a HCV-positive donor, 62.9% were male, 55.5% were White, and 51.4% attained a high school degree or higher. The numbers of DDKT using kidneys from HCV + donors increased during the study period; however, the nonuse of such kidneys has increased. Conclusion: Interventions targeting willingness to accept a HCV-positive donor may simultaneously increase access to transplant and support policies to reduce organ nonuse.
- 11 March 2025
- Published by Wolters Kluwer Health in Transplantation
- Vol. 109 (8) , 1413-1424
Access to Transplant for African American and Latino Patients Under the 2014 US Kidney Allocation System
Background. Kidney transplant offers better outcomes and reduced costs compared with chronic dialysis. However, racial and ethnic disparities in access to kidney transplant persist despite efforts to expand access to transplant and improve the equity of deceased donor allocation. Our objective was to evaluate after listing the association of race and ethnicity with access to deceased donor kidney transplant (DDKT) after changes to the allocation system in 2014. Methods. This retrospective study evaluated access to DDKT after listing since the implementation of the 2014 kidney allocation system. Waitlist status and transplant outcomes were ascertained from data from the Scientific Registry of Transplant Recipients. Our analysis included every adult kidney transplant candidate on the waiting list in the US from January 1, 2015, through June 30, 2023. Results. A total of 290 763 candidates were on the waiting list for DDKT during the study period. Of these, 36.4% of candidates were African American and 22.2% were Latino. Compared with White non-Latino patients, access to DDKT after listing was reduced for African American (unadjusted hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.92-0.94) and Latino individuals (unadjusted HR, 0.88; 95% CI, 0.87-0.90). After controlling for demographic and clinical factors, these differences in access to transplant widened substantially for African American (HR, 0.78; 95% CI, 0.77-0.80) and Latino patients (HR, 0.73; 95% CI, 0.72-0.74). Conclusions. African American and Latino patients had reduced access to DDKT after listing. More effective approaches to improving access for African American and Latino individuals after listing are needed. Export
- 11 March 2025
- Published by Wolters Kluwer Health in Transplantation
- Vol. 109 (8) , 1413-1424
Access to Transplant for African American and Latino Patients Under the 2014 US Kidney Allocation System
Background. Kidney transplant offers better outcomes and reduced costs compared with chronic dialysis. However, racial and ethnic disparities in access to kidney transplant persist despite efforts to expand access to transplant and improve the equity of deceased donor allocation. Our objective was to evaluate after listing the association of race and ethnicity with access to deceased donor kidney transplant (DDKT) after changes to the allocation system in 2014. Methods. This retrospective study evaluated access to DDKT after listing since the implementation of the 2014 kidney allocation system. Waitlist status and transplant outcomes were ascertained from data from the Scientific Registry of Transplant Recipients. Our analysis included every adult kidney transplant candidate on the waiting list in the US from January 1, 2015, through June 30, 2023. Results. A total of 290 763 candidates were on the waiting list for DDKT during the study period. Of these, 36.4% of candidates were African American and 22.2% were Latino. Compared with White non-Latino patients, access to DDKT after listing was reduced for African American (unadjusted hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.92-0.94) and Latino individuals (unadjusted HR, 0.88; 95% CI, 0.87-0.90). After controlling for demographic and clinical factors, these differences in access to transplant widened substantially for African American (HR, 0.78; 95% CI, 0.77-0.80) and Latino patients (HR, 0.73; 95% CI, 0.72-0.74). Conclusions. African American and Latino patients had reduced access to DDKT after listing. More effective approaches to improving access for African American and Latino individuals after listing are needed. Export
- 2 December 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (12) , e70043
Randomized Controlled Trial to Evaluate a New Tool to Support Patient Decision‐making on Transplant Centers
Patients are not always aware of listing criteria and offer acceptance across transplant programs. Factors such as age and body mass index can impact access to transplants as centers have different candidate criteria. Therefore, we created a transplant center search tool (transplantcentersearch.org) (TCST) to help patients find comparative information on transplant programs. We conducted a cross‐over randomized controlled trial (RCT) to assess whether the TCST improved comprehension compared to the existing Scientific Registry of Transplant Recipients website among adults seeking kidney transplants at two centers. To assess comprehension participants were asked to use the TCST and the SRTR website to identify which transplant program within a prespecified area had the most recipients over 70 years of age; and which programs had the most recipients with BMI >40. Participants were asked to provide qualitative feedback on using both websites. Sixty‐eight candidates participated in the RCT. Participants were more likely to identify the correct program when using the TCST compared to the existing SRTR website (OR 8.13, 95% CI 1.87–35.33). Participants stated they preferred the TCST over the SRTR website (52.9% vs. 25.0%, respectively, p = 0.009). With increased comprehension, patients would be better equipped to identify programs that transplant patients like them.Trial Registration: ClinicalTrials.gov identifier: NCT03610555
- 2 December 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (12) , e70043
Randomized Controlled Trial to Evaluate a New Tool to Support Patient Decision‐making on Transplant Centers
Patients are not always aware of listing criteria and offer acceptance across transplant programs. Factors such as age and body mass index can impact access to transplants as centers have different candidate criteria. Therefore, we created a transplant center search tool (transplantcentersearch.org) (TCST) to help patients find comparative information on transplant programs. We conducted a cross‐over randomized controlled trial (RCT) to assess whether the TCST improved comprehension compared to the existing Scientific Registry of Transplant Recipients website among adults seeking kidney transplants at two centers. To assess comprehension participants were asked to use the TCST and the SRTR website to identify which transplant program within a prespecified area had the most recipients over 70 years of age; and which programs had the most recipients with BMI >40. Participants were asked to provide qualitative feedback on using both websites. Sixty‐eight candidates participated in the RCT. Participants were more likely to identify the correct program when using the TCST compared to the existing SRTR website (OR 8.13, 95% CI 1.87–35.33). Participants stated they preferred the TCST over the SRTR website (52.9% vs. 25.0%, respectively, p = 0.009). With increased comprehension, patients would be better equipped to identify programs that transplant patients like them.Trial Registration: ClinicalTrials.gov identifier: NCT03610555
- 23 August 2024
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 24 (5) , 1-9
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients
African American (AA) kidney transplant recipients (KTRs) have poor outcomes, which may in-part be due to tacrolimus (TAC) sub-optimal immunosuppression. We previously determined the common genetic regulators of TAC pharmacokinetics in AAs which were CYP3A5 *3, *6, and *7. To identify low-frequency variants that impact TAC pharmacokinetics, we used extreme phenotype sampling and compared individuals with extreme high (n = 58) and low (n = 60) TAC troughs (N = 515 AA KTRs). Targeted next generation sequencing was conducted in these two groups. Median TAC troughs in the high group were 7.7 ng/ml compared with 6.3 ng/ml in the low group, despite lower daily doses of 5 versus 12 mg, respectively. Of 34,542 identified variants across 99 genes, 1406 variants were suggestively associated with TAC troughs in univariate models (p-value < 0.05), however none were significant after multiple testing correction. We suggest future studies investigate additional sources of TAC pharmacokinetic variability such as drug-drug-gene interactions and pharmacomicrobiome.
- 23 August 2024
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 24 (5) , 1-9
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients
African American (AA) kidney transplant recipients (KTRs) have poor outcomes, which may in-part be due to tacrolimus (TAC) sub-optimal immunosuppression. We previously determined the common genetic regulators of TAC pharmacokinetics in AAs which were CYP3A5 *3, *6, and *7. To identify low-frequency variants that impact TAC pharmacokinetics, we used extreme phenotype sampling and compared individuals with extreme high (n = 58) and low (n = 60) TAC troughs (N = 515 AA KTRs). Targeted next generation sequencing was conducted in these two groups. Median TAC troughs in the high group were 7.7 ng/ml compared with 6.3 ng/ml in the low group, despite lower daily doses of 5 versus 12 mg, respectively. Of 34,542 identified variants across 99 genes, 1406 variants were suggestively associated with TAC troughs in univariate models (p-value < 0.05), however none were significant after multiple testing correction. We suggest future studies investigate additional sources of TAC pharmacokinetic variability such as drug-drug-gene interactions and pharmacomicrobiome.
- Open Access
- 31 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0303446
Polygenic risk score for acute rejection based on donor-recipient non-HLA genotype mismatch
Background: Acute rejection (AR) after kidney transplantation is an important allograft complication. To reduce the risk of post-transplant AR, determination of kidney transplant donor-recipient mismatching focuses on blood type and human leukocyte antigens (HLA), while it remains unclear whether non-HLA genetic mismatching is related to post-transplant complications. Methods: We carried out a genome-wide scan (HLA and non-HLA regions) on AR with a large kidney transplant cohort of 784 living donor-recipient pairs of European ancestry. An AR polygenic risk score (PRS) was constructed with the non-HLA single nucleotide polymorphisms (SNPs) filtered by independence (r2 < 0.2) and P-value (< 1×10−3) criteria. The PRS was validated in an independent cohort of 352 living donor-recipient pairs. Results: By the genome-wide scan, we identified one significant SNP rs6749137 with HR = 2.49 and P-value = 2.15×10−8. 1,307 non-HLA PRS SNPs passed the clumping plus thresholding and the PRS exhibited significant association with the AR in the validation cohort (HR = 1.54, 95% CI = (1.07, 2.22), p = 0.019). Further pathway analysis attributed the PRS genes into 13 categories, and the over-representation test identified 42 significant biological processes, the most significant of which is the cell morphogenesis (GO:0000902), with 4.08 fold of the percentage from homo species reference and FDR-adjusted P-value = 8.6×10−4. Conclusions: Our results show the importance of donor-recipient mismatching in non-HLA regions. Additional work will be needed to understand the role of SNPs included in the PRS and to further improve donor-recipient genetic matching algorithms. Trial registry: Deterioration of Kidney Allograft Function Genomics (NCT00270712) and Genomics of Kidney Transplantation (NCT01714440) are registered on ClinicalTrials.gov.
- 31 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0303446
Open AccessPolygenic risk score for acute rejection based on donor-recipient non-HLA genotype mismatch
Background: Acute rejection (AR) after kidney transplantation is an important allograft complication. To reduce the risk of post-transplant AR, determination of kidney transplant donor-recipient mismatching focuses on blood type and human leukocyte antigens (HLA), while it remains unclear whether non-HLA genetic mismatching is related to post-transplant complications. Methods: We carried out a genome-wide scan (HLA and non-HLA regions) on AR with a large kidney transplant cohort of 784 living donor-recipient pairs of European ancestry. An AR polygenic risk score (PRS) was constructed with the non-HLA single nucleotide polymorphisms (SNPs) filtered by independence (r2 < 0.2) and P-value (< 1×10−3) criteria. The PRS was validated in an independent cohort of 352 living donor-recipient pairs. Results: By the genome-wide scan, we identified one significant SNP rs6749137 with HR = 2.49 and P-value = 2.15×10−8. 1,307 non-HLA PRS SNPs passed the clumping plus thresholding and the PRS exhibited significant association with the AR in the validation cohort (HR = 1.54, 95% CI = (1.07, 2.22), p = 0.019). Further pathway analysis attributed the PRS genes into 13 categories, and the over-representation test identified 42 significant biological processes, the most significant of which is the cell morphogenesis (GO:0000902), with 4.08 fold of the percentage from homo species reference and FDR-adjusted P-value = 8.6×10−4. Conclusions: Our results show the importance of donor-recipient mismatching in non-HLA regions. Additional work will be needed to understand the role of SNPs included in the PRS and to further improve donor-recipient genetic matching algorithms. Trial registry: Deterioration of Kidney Allograft Function Genomics (NCT00270712) and Genomics of Kidney Transplantation (NCT01714440) are registered on ClinicalTrials.gov.
- 11 January 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (4) , e14893
Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers
Kidney transplant recipients carrying the CYP3A5*1 allele have lower tacrolimus troughs, and higher dose requirements compared to those with the CYP3A5*3/*3 genotype. However, data on the effect of CYP3A5 alleles on post‐transplant tacrolimus management are lacking. The effect of CYP3A5 metabolism phenotypes on the number of tacrolimus dose adjustments and troughs in the first 6 months post‐transplant was evaluated in 78 recipients (64% Caucasians). Time to first therapeutic concentration, percentage of time in therapeutic range (TTR), and estimated glomerular filtration rate (eGFR) were also evaluated. Fifty‐five kidney transplant recipients were CYP3A5 poor metabolizers (PM), 17 were intermediate metabolizers (IM), and 6 were extensive metabolizers (EM). Compared to PMs, EMs/IMs had significantly more dose adjustments (6.1 vs. 8.1, p = .015). Overall, 33.82% of trough measurements resulted in a dose change. There was no difference in the number of tacrolimus trough measurements between PMs and EM/IMs. The total daily tacrolimus dose requirements were higher in EMs and IMs compared to PMs (<.001). TTR was ∼50% in the PMs and EMs/IMs groups. CYP3A5 EM/IM metabolizers have more tacrolimus dose changes and higher dose requirements which increases clinical management complexity. Larger studies are needed to assess the cost and benefits of including genotyping data to improve clinical management.
- 11 January 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (4) , e14893
Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers
Kidney transplant recipients carrying the CYP3A5*1 allele have lower tacrolimus troughs, and higher dose requirements compared to those with the CYP3A5*3/*3 genotype. However, data on the effect of CYP3A5 alleles on post‐transplant tacrolimus management are lacking. The effect of CYP3A5 metabolism phenotypes on the number of tacrolimus dose adjustments and troughs in the first 6 months post‐transplant was evaluated in 78 recipients (64% Caucasians). Time to first therapeutic concentration, percentage of time in therapeutic range (TTR), and estimated glomerular filtration rate (eGFR) were also evaluated. Fifty‐five kidney transplant recipients were CYP3A5 poor metabolizers (PM), 17 were intermediate metabolizers (IM), and 6 were extensive metabolizers (EM). Compared to PMs, EMs/IMs had significantly more dose adjustments (6.1 vs. 8.1, p = .015). Overall, 33.82% of trough measurements resulted in a dose change. There was no difference in the number of tacrolimus trough measurements between PMs and EM/IMs. The total daily tacrolimus dose requirements were higher in EMs and IMs compared to PMs (<.001). TTR was ∼50% in the PMs and EMs/IMs groups. CYP3A5 EM/IM metabolizers have more tacrolimus dose changes and higher dose requirements which increases clinical management complexity. Larger studies are needed to assess the cost and benefits of including genotyping data to improve clinical management.
- Open Access
- 11 February 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (8) , 1517-1519
Deconstructing Silos of Knowledge Around Lung Transplantation to Support Patients: A Patient-specific Search of Scientific Registry of Transplant Recipients Data
- 11 February 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (8) , 1517-1519
Open AccessDeconstructing Silos of Knowledge Around Lung Transplantation to Support Patients: A Patient-specific Search of Scientific Registry of Transplant Recipients Data
- 14 July 2020
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 45 (6) , 1457-1465
Pharmacogenomics in kidney transplant recipients and potential for integration into practice
What is known and objective Pharmacogenomic biomarkers are now used in many clinical care settings and represent one of the successes of precision medicine. Genetic variants are associated with pharmacokinetic and pharmacodynamic changes leading to medication adverse effects and changes in clinical response. Actionable pharmacogenomic variants are common in transplant recipients and have implications for medications used in transplant, but yet are not broadly incorporated into practice. Methods From the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group guidelines, and PharmGKB databases, 12 pharmacogenomic genes with 30 variants were selected and used to create diplotypes and actionable pharmacogenomic phenotypes. A total of 853 kidney allograft recipients who had genomic information available from a genome‐wide association study were included. Results Each recipient had at least one actionable pharmacogenomic diplotype/phenotype, whereas the majority (58%) had three or four actionable diplotypes/phenotypes and 17.4% had five or more among the 12 genes. The participants carried actionable diplotypes/phenotypes for multiple medications, including tacrolimus, azathioprine, clopidogrel, warfarin, simvastatin, voriconazole, antidepressants and proton‐pump inhibitors. What is new and conclusion Pharmacogenomic variants are common in transplant recipients, and transplant recipients receive medications that have actionable variants. Clinical trial Genomics of Transplantation, clinicaltrials.gov (NCT01714440).
- 14 July 2020
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 45 (6) , 1457-1465
Pharmacogenomics in kidney transplant recipients and potential for integration into practice
What is known and objective Pharmacogenomic biomarkers are now used in many clinical care settings and represent one of the successes of precision medicine. Genetic variants are associated with pharmacokinetic and pharmacodynamic changes leading to medication adverse effects and changes in clinical response. Actionable pharmacogenomic variants are common in transplant recipients and have implications for medications used in transplant, but yet are not broadly incorporated into practice. Methods From the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group guidelines, and PharmGKB databases, 12 pharmacogenomic genes with 30 variants were selected and used to create diplotypes and actionable pharmacogenomic phenotypes. A total of 853 kidney allograft recipients who had genomic information available from a genome‐wide association study were included. Results Each recipient had at least one actionable pharmacogenomic diplotype/phenotype, whereas the majority (58%) had three or four actionable diplotypes/phenotypes and 17.4% had five or more among the 12 genes. The participants carried actionable diplotypes/phenotypes for multiple medications, including tacrolimus, azathioprine, clopidogrel, warfarin, simvastatin, voriconazole, antidepressants and proton‐pump inhibitors. What is new and conclusion Pharmacogenomic variants are common in transplant recipients, and transplant recipients receive medications that have actionable variants. Clinical trial Genomics of Transplantation, clinicaltrials.gov (NCT01714440).